Key Highlights

● Absci traded at $10.14 by late morning.

● No company announcement explained the rise.

● Recursion and Tempus AI also climbed.

● The iShares Biotechnology ETF climbed sharply.

Absci (NASDAQ:ABSI) jumped in Friday's session, trading at $10.14 by late morning and ranking among the strongest small-cap health care stocks on a list of big movers. No company announcement explained the rise. Instead, Absci moved with a powerful rally across biotechnology that lifted dozens of names at once.

Recursion Pharmaceuticals (NASDAQ:RXRX), another company built around AI-led drug discovery, also climbed, as did Tempus AI, which applies data and AI to diagnostics. Their shared rise suggested investors were treating the session as a broad bet on the sector rather than reacting to anything specific to Absci.

What Absci does

Absci uses generative artificial intelligence combined with wet-lab biology to design antibodies and other protein-based drugs. The company's pitch is that AI models can explore far more potential drug designs than traditional methods, and that rapid lab testing can then validate the best candidates. It works both on its own internal programmes and with pharmaceutical partners.

Companies like Absci sit at the intersection of two themes that investors have embraced in 2026: artificial intelligence and biotech. That can make the shares especially responsive when either theme is in favour, and on Friday both were.

Two tailwinds at once

The biotech rally had a clear trigger. A report described a planned public-private initiative involving the National Institutes of Health to accelerate cancer-vaccine research, with a launch expected in December. Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) soared, and the iShares Biotechnology ETF climbed sharply. Health care ranked among the best-performing S&P 500 sectors on the day.

At the same time, artificial-intelligence stocks were bouncing back. On Thursday, a report that OpenAI's annualised Revenue was about $50 billion, roughly $20 billion below a figure that had circulated earlier, triggered a sell-off in AI-linked shares. On Friday, software and data names recovered strongly, with Palantir (NASDAQ:PLTR), Microsoft (NASDAQ:MSFT) and Oracle (NYSE:ORCL) all rallying. That shift in mood helped companies marketed around AI, including those applying it to drug development.

Absci is a small company, and low-priced biotech shares can swing sharply in both directions, particularly on days when sector momentum draws in short-term traders.

Small caps still under pressure

Despite gains like Absci's, the Russell 2000 had another tough week. The small-cap benchmark rose 12.85 points to 2,806.98 on Friday but fell 25.91 points over the week, its fifth straight weekly decline. The S&P 500, by contrast, gained 46.18 points to 7,811.54, leaving it just shy of its record close.

High interest rates are part of the problem. The 10-year Treasury Yield is close to a 24-year high, and the Federal Reserve raised rates in September for the first time since 2023. Minutes of that meeting showed officials saw another increase as likely appropriate by year end. Research-stage biotechs, which often depend on fresh funding, are especially sensitive to tighter financial conditions.

Daniela Hathorn, senior market analyst, summed up what investors want to see: "Strong Earnings combined with moderating Inflation would offer the most supportive backdrop for equities".

NIH Initiative Details Could Keep Attention on Biotech

Investors will look for clearer details on the NIH-linked cancer-vaccine initiative, which could keep attention on biotech, and for any Partnership or pipeline updates from Absci. The bigger macro test comes with September consumer price data on Wednesday, October 14. Major bank earnings run from October 13 to 16, and the Fed meets on October 27 to 28. Stock exchanges stay open on Monday, October 12, though the Bond Market observes Columbus Day.